Information Provided By: 
Fly News Breaks for September 20, 2017
JAZZ
Sep 20, 2017 | 08:25 EDT
After speaking with two AML specialists, BMO Capital analyst Gary Nachman reports that their "early experience" with Jazz's Vyxeos drug "has been positive." They do not expect their patients to have major problems getting reimbursed for the drug, and they expect to use it significantly in the future, NAchman reported. The analyst thinks that higher than expected uptake of the drug could cause the stock;'s multiple to rise, and he keeps an Outperform rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
